Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Cataract Refract Surg ; 41(6): 1210-6, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26096523

RESUMO

PURPOSE: To assess the incidence, culture results, and visual outcomes of infectious keratitis after laser in situ keratomileusis (LASIK) and surface ablation when topical moxifloxacin was added to postoperative prophylaxis with tobramycin. SETTING: Clínica Baviera, Instituto Oftalmológico Europeo, Bilbao, Spain. DESIGN: Retrospective case series review. METHODS: The medical records of 55 255 patients (108 014 eyes) who had LASIK and surface ablation were reviewed to identify cases of infectious keratitis. The incidence, risk factors, clinical course, days to diagnosis, treatment, and final visual outcomes were recorded. These data were compared with previously published data of 221 437 eyes that received postoperative tobramycin alone. RESULTS: Post-LASIK infectious keratitis was diagnosed in 10 eyes (9 patients) and post-surface ablation infectious keratitis in 11 eyes (10 patients). The onset of infection was early in 40.00% of cases after LASIK and in 36.36% after surface ablation. Cultures were positive in 2 cases after surface ablation. Immediate flap lifting and irrigation with antibiotics were performed in all eyes after LASIK. The final corrected distance visual acuity was 20/20 or better in 7 cases after LASIK (70.00%) and 7 cases after surface ablation (63.64%) and 20/40 or better in all cases after LASIK or surface ablation. CONCLUSIONS: The incidence of infectious keratitis decreased from 0.025% to 0.011% (P < .001) per procedure after LASIK and from 0.200% to 0.066% (P < .001) after surface ablation. Infectious keratitis was less frequent after LASIK than after surface ablation. The frequency of infection, mainly early-onset infection, was lower when the postoperative treatment was tobramycin and moxifloxacin rather than tobramycin alone. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.


Assuntos
Antibioticoprofilaxia , Úlcera da Córnea/epidemiologia , Infecções Oculares Bacterianas/epidemiologia , Fluoroquinolonas/uso terapêutico , Ceratomileuse Assistida por Excimer Laser In Situ , Complicações Pós-Operatórias , Tobramicina/uso terapêutico , Administração Tópica , Adulto , Idoso , Antibacterianos/uso terapêutico , Úlcera da Córnea/microbiologia , Úlcera da Córnea/prevenção & controle , Quimioterapia Combinada , Infecções Oculares Bacterianas/microbiologia , Infecções Oculares Bacterianas/prevenção & controle , Feminino , Humanos , Incidência , Lasers de Excimer/uso terapêutico , Masculino , Pessoa de Meia-Idade , Moxifloxacina , Miopia/cirurgia , Soluções Oftálmicas , Estudos Retrospectivos , Fatores de Risco , Acuidade Visual/fisiologia , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA